RxDoctor Payments Data

James Martin, MD

Hematology & Oncology · Cleveland, OHNPI 1558708693

Payments from drug & device makers

$291,502in general payments, 2019–2025

Across 89 payments — averaging $3275.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$174K
  • Genmab A/s$52K
  • Pfizer$19K
  • Stemline Therapeutics Inc.$19K
  • Seagen Inc.$14K
  • Genentech, Inc.$10K
  • plus $4K from 19 others

What the payments were for

  • Consulting fees$1,9283%
  • Speaking & faculty fees$49,68389%
  • Travel & lodging$8422%
  • Food & beverage$3,2016%
  • Education$1980%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$291,502 in reported general payments places this provider in the 75th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$37,692
Medicare patients
171
Services billed
396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VerzenioAbemaciclib22$339,380
IbrancePalbociclib20$318,643
KisqaliRibociclib Succinate15$215,670
LynparzaOlaparib13$142,225
EliquisApixaban14$9,879
Exemestane34$7,083
Anastrozole279$4,150
Ondansetron Hcl23$2,161
Tamoxifen Citrate61$1,870
Letrozole74$1,376
Acyclovir11$214
Prochlorperazine Maleate12$193
Dexamethasone15$113
Gabapentin13$67
Olanzapine13$49

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCVerzenio, Olanzapine$25$339,42935 claims
PfizerIbrance, Eliquis$19,254$328,52234 claims
NovartisKisqali$65$215,67015 claims
AstraZenecaLynparza$15$142,22513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →